Top Story Today
The Lp(a) Heart Drug That Crushed Its Target and Still Failed
Novartis's pelacarsen lowered Lp(a) by roughly 80% in over 8,000 patients, and it made absolutely no difference. Heart attacks, strokes, and cardiac deaths kept happening at the same rate as placebo in the landmark Lp(a)HORIZON trial. The failure doesn't just sink one drug; it undercuts the entire genetic thesis behind Lp(a)-lowering, a hypothesis that Amgen, Eli Lilly, and others have staked billions on. Supporters argue that siRNAs from Amgen and Lilly push Lp(a) down even further (above 90%), and that extra suppression might matter. But the burden of proof just shifted dramatically.
Why it matters: If genetics can tell you where to aim but still miss in a clinical trial, it raises hard questions about genetically validated drug targets across all of medicine, not just cardiology.
Read more →Clinical and Regulatory
A Blood Test, Not a Scan, Now Triggers a Breast Cancer Drug Switch
The FDA granted accelerated approval to AstraZeneca's camizestrant for HR-positive breast cancer, with a label that's more radical than the drug itself: doctors should switch treatment when a blood test detects an ESR1 resistance mutation, before scans show any progression. The approval overruled a 6-to-3 advisory committee vote against the drug. If post-approval data holds up, this liquid biopsy-driven framework could reshape treatment decisions across cancer types.
Read more →Two Pharma Giants Pause Autoimmune CAR-T, and the Pattern Is Getting Hard to Ignore
Bristol Myers Squibb paused enrollment in its autoimmune CAR-T trials days after Novartis halted eight programs following three patient deaths. Both companies use CD19-targeted therapies with overlapping mechanisms, and both have now flagged inflammatory complications. The emerging safety pattern threatens one of cell therapy's most promising expansion areas, where patients aren't terminally ill and tolerance for risk is far lower.
Read more →Sarepta Gets a Black Box Warning, Fires 36% of Staff, and Bets on Survival
Sarepta's Elevidys, the only approved gene therapy for Duchenne muscular dystrophy, now carries the FDA's most serious safety label after reports of fatal liver failure. The company laid off 500 employees and is pivoting toward siRNA technology. Investors were relieved the FDA didn't pull the drug entirely, and $400 million in annual savings gave the company a survival path.
Read more →Deals and Strategy
Italy's Biggest Private Pharma Just Dropped $771M on a Chinese GLP-1 Drug
Menarini Group, a 140-year-old family-owned Italian pharma company, licensed European rights to Gan & Lee's biweekly GLP-1 injectable for up to 726 million euros. The deal is part of a massive wave of Western companies licensing obesity drugs from Chinese biotechs, with AstraZeneca, Novo Nordisk, Merck, and Pfizer all inking similar cross-border agreements worth billions.
Read more →Sangamo Gets Carved Up: PTC Grabs the Drug, Lilly Takes the Toolbox
Gene therapy pioneer Sangamo Therapeutics is being sold for parts in bankruptcy court. PTC Therapeutics paid $111 million for a nearly FDA-ready Fabry disease gene therapy, while Eli Lilly scooped up decades of gene-editing technology for just $50 million. Combined, a company once valued in the billions fetched roughly $163.55 million in guaranteed cash.
Read more →Public Health
The Only Syphilis Drug for Pregnant Women Just Got Recalled. There Is No Plan B.
Pfizer recalled lots of Bicillin L-A, the sole FDA-approved benzathine penicillin product in the U.S., after finding particulate contamination. No alternative antibiotic exists for treating syphilis during pregnancy. With congenital syphilis cases up 700% since 2015 and the shortage already running since 2023, the CDC is urging clinics to reserve remaining doses exclusively for pregnant patients and infants.
Read more →